Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy

Eur Heart J. 2021 Aug 17;42(31):2973-2985. doi: 10.1093/eurheartj/ehab277.

Affiliation

¹ Department of Cardiovascular Medicine and Pneumology, Catholic University, Roma, Italy.

PMID: 34110420
DOI: 10.1093/eurheartj/ehab277

No abstract available

MeSH terms

Clopidogrel
Humans
Percutaneous Coronary Intervention*
Prasugrel Hydrochloride / therapeutic use
Purinergic P2Y Receptor Antagonists
Ticagrelor / therapeutic use

Substances

Purinergic P2Y Receptor Antagonists
Clopidogrel
Prasugrel Hydrochloride
Ticagrelor